Redenlab Inc is an industry leading neuroscience focussed tech bio. We use speech and language biometrics to improve decision-making in clinical trials. Whether the trials take place in clinic, at home, or virtually, our tests are sensitive and reliable, accurately detecting subtle changes caused by disease or treatment. Our speech software and hardware solutions meet all the regulatory requirements for data security and integrity in clinical trials, including 21 CFR Part 11 and HIPAA.
Follow us to find out more about our groundbreaking projects and explore the future of speech analysis at www.redenlab.com.
Company Details
- Employees
- 33
- Founded
- -
- Address
- 585 Collins St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- redenlab.com
- Keywords
- neuroscience, speech, language, dysphagia, clinical trials, analysis pipeline, biometrics, neurology, acoustics, science, technology, biomarkers, pharmaceuticals, rare disease, dementia, ataxia, parkinson's disease, huntington's disease, motor neurone disease, autism, neurodegeneration, neurodevelopment.
- HQ
- Melbourne, Victoria
Redenlab Questions
Redenlab's website is redenlab.com
Redenlab's LinkedIn profile is https://www.linkedin.com/company/redenlab
Redenlab has
33 employees.
View email and phone details for 33
employees at Redenlab.
Redenlab's industry is
Biotechnology Research
Redenlab's top competitors are
Canary Speech,
Mitsubishi Tanabe Pharma America,
Quantificare,
Impetus Consulting Group,
Curebase,
Blue Spark Technologies,
Royal Trinity Hospice,
Local Edge Marketing,
Capgemini,
Uom Speech Pathology.
Redenlab's categories are Biotechnology Research
Redenlab's founding year is 2017
